NL-OMON42040已完成不适用
Evaluation of 3'-deoxy-3'-[18F]fluorothymidine -PET and diffusion weighted imaging -MRI in patients with early stage non-small cell lung cancer treated with a platinum-based doublet as preoperative chemotherapy. - Preoperative PET and MR study in lung cancer patients
European Organisation for Research in Treatment of Cancer (EORTC)0 个研究点目标入组 4 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational invasive
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Age >= 18 years
- •* WHO performance status 0-1
- •* Histologically or cytological confirmed clinical stage II-IIIA non-small cell lung carcinoma (NSCLC), according to 7th TNM classification (NOTE: patients with resectable N2 disease are also eligible)
- •* Baseline standard imaging assessment & staging should be performed within 6 weeks prior to planned treatment start.
- •* Patients must be candidate for curative intent surgery, and must be expected to complete the treatment.
- •* No prior or current anticancer treatment for NSCLC, pre-operative therapy will include only chemotherapeutic drugs (pemetrexed is contraindicated), no other biological, targeted or radiotherapy is allowed
- •* No treatment with any investigational drug substance within 4 weeks prior to registration.
- •* No other malignancies in the 3 years prior to study entry with the exception of surgically cured carcinoma in situ of the cervix, in situ breast cancer, incidental finding of stage T1a or T1b prostate cancer, and basal/squamous cell carcinoma of the skin
- •* No evidence of any medical condition which would impair the ability of the patient to participate in the trial or might preclude therapy with chemotherapeutic drugs according to routine medical practice (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease, known dihydropyrimidine dehydrogenase deficiency, active infection, uncontrolled diabetes mellitus; uncontrolled arterial hypertension, history of unstable myocardial infarction)
- •* Adequate hematology and biochemical investigations, (should be done maximum 6 weeks before treatment starts)
- •* Normal bone marrow function based on routine blood samples, i.e. neutrophils >= 1.5 x 109/L, platelets >= 75 x 109/L, hemoglobin >= 10.0 g/dL
- •* Normal kidney function creatinine clearance >= 60 mL/min,
- •* Normal liver function assessed by routine laboratory examinations, i.e. bilirubin < 1.5 x upper limit of normal (ULN), ALT< 3 x ULN
- •* Patients must not have any contraindication for 18F-FLT-PET/CT or MRI procedures.
- •* Patient primary lung tumor larger than 20 mm in diameter (measured by diagnostic CT or MRI).
- •* Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test before trial registration.
- •* Patients of childbearing / reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 6 months after the last study procedure. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
- •* Female subjects who are breast feeding should discontinue nursing before trial registration.
- •* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial.
- •* Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.
排除标准
- •- Does not meet the inclusion criteria
- •- Younger than 50 years
研究者
相似试验
已完成
2 期
Study of Clinical Usefulness of 18F-fluorothymidine(FLT) PET/CT in Ditection of Peritoneal Metastases of Gastric CancerJPRN-UMIN000009329Department of Gastrointestinal Oncology, National Cancer Center Hospital in Japan40
尚未招募
不适用
Movember substudyNL-OMON26162VU university Medical Center10
已完成
2 期
Phase II study of 18 F fluorothymidine Positron Emission Tomography (FLT-PET) in the follow up of glioblastoma multiforme (GBM) patients treated with combined radiotherapie and chemotherapybraintumor10029211glioblastoma multiformeNL-OMON38320niversitair Medisch Centrum Groningen30
已完成
不适用
A study of usefulness of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the initial staging and assessment of response to treatment in locally advanced breast cancerCTRI/2018/04/013455Sri Venkateswara Institute of Medical Sciences
Unknown
不适用
Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative ChemoNon-small Cell Lung CarcinomaNCT02273271European Organisation for Research and Treatment of Cancer - EORTC31